Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Circadian clock dysfunction in human omental fat links obesity to metabolic inflammation.

Maury E., Navez B., Brichard SM.

Prospective Study on Hip, published in Nat Commun (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Nat Commun (2021)
Country
England
Reported sample size
—
Source database
PubMed
PMID
33888702
PMCID
PMC8062496
DOI
10.1038/s41467-021-22571-9
Citations
61

Abstract (original English)

To unravel the pathogenesis of obesity and its complications, we investigate the interplay between circadian clocks and NF-κB pathway in human adipose tissue. The circadian clock function is impaired in omental fat from obese patients. ChIP-seq analyses reveal that the core clock activator, BMAL1 binds to several thousand target genes. NF-κB competes with BMAL1 for transcriptional control of some targets and overall, BMAL1 chromatin binding occurs in close proximity to NF-κB consensus motifs. Obesity relocalizes BMAL1 occupancy genome-wide in human omental fat, thereby altering the transcription of numerous target genes involved in metabolic inflammation and adipose tissue remodeling. Eventually, clock dysfunction appears at early stages of obesity in mice and is corrected, together with impaired metabolism, by NF-κB inhibition. Collectively, our results reveal a relationship between NF-κB and the molecular clock in adipose tissue, which may contribute to obesity-related complications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
ARNTL Transcription FactorsAdipocytesAdiponectinAdultAnimalsBiopsyCase-Control StudiesCells, CulturedChromatin Immunoprecipitation SequencingCircadian Clocks

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research